These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38631712)

  • 21. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
    Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
    Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.
    Weinstein B; Muresan B; Solano S; de Macedo AV; Lee Y; Su YC; Ahn Y; Henriquez G; Camargo C; Kim GJ; Carpenter DO
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
    Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
    Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
    Zurko J; Ramdial J; Shadman M; Ahmed S; Szabo A; Iovino L; Tomas AA; Sauter C; Perales MA; Shah NN; Acharya UH; Jacobson C; Soiffer RJ; Wang T; Komanduri KV; Jaglowski S; Kittai AS; Denlinger N; Iqbal M; Kharfan-Dabaja MA; Ayala E; Chavez J; Jain M; Locke FL; Samara Y; Budde LE; Mei MG; Pia AD; Feldman T; Ahmed N; Jacobs R; Ghosh N; Dholaria B; Oluwole OO; Hess B; Hassan A; Kenkre VP; Reagan P; Awan F; Nieto Y; Hamadani M; Herrera AF
    Haematologica; 2023 Jan; 108(1):98-109. PubMed ID: 35833303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
    Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30
    Zhang P; Yang X; Cao Y; Wang J; Zhou M; Chen L; Wei J; Mao Z; Wang D; Xiao Y; Zhu H; Zhang S; Zhang T; Zhang Y; Zhou J; Huang L
    Exp Hematol Oncol; 2022 Oct; 11(1):72. PubMed ID: 36253833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
    [No Abstract]   [Full Text] [Related]  

  • 35. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
    Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
    J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 37. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
    Westin J; Sehn LH
    Blood; 2022 May; 139(18):2737-2746. PubMed ID: 35240677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
    Westin JR; Locke FL; Dickinson M; Ghobadi A; Elsawy M; van Meerten T; Miklos DB; Ulrickson ML; Perales MA; Farooq U; Wannesson L; Leslie L; Kersten MJ; Jacobson CA; Pagel JM; Wulf G; Johnston P; Rapoport AP; Du L; Vardhanabhuti S; Filosto S; Shah J; Snider JT; Cheng P; To C; Oluwole OO; Sureda A
    Clin Cancer Res; 2023 May; 29(10):1894-1905. PubMed ID: 36999993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.